A novel predictor for stratifying pancreatic cancer patients to DNA damage checkpoint inhibitors

Petranel Ferrao

University of Melbourne

Dr Ferrao has over 15 years of research, teaching and commercial experience in the biomedical sciences. With a passion for translational research she has led innovative research to novel discoveries that have contributed to the advancement of cancer treatments in clinical development. Building upon her training and expertise in Receptor Tyrosine kinases, signalling and drug resistance, she focuses on two main areas: defining predictors of therapy response and investigating mechanisms of drug resistance to cancer treatments. She has a clear vision for contributing to precision medicine through innovative research by advancing the personalised use of current/new therapies for patient benefit.


Introduction CHK1 is a key DNA damage checkpoint kinase involved in cell cycle arrest and DNA repair. CHK1 inhibitors (CHK1i) were originally developed as chemo-potentiators in cancers with p53 mutations. Several CHK1i have... [ view full abstract ]


  1. Dannel Yeo (University of Melbourne)
  2. Robert Jorissen (The Walter and Eliza Hall Institute of Medical Research)
  3. Mehrdad Nikfarjam (University of Melbourne)
  4. Petranel Ferrao (University of Melbourne)

Topic Area

Biomarkers and diagnostics, liquid biopsy, imaging, biochip/microarray technologies, advan


OS2c-A » Biomarkers and diagnostics, imaging, biochip/microarray technologies (17:00 - Tuesday, 26th June, Amphitheater)

Presentation Files

The presenter has not uploaded any presentation files.